title: [Bullous pemphigoid and acquired haemophilia].
authors.forename: N
authors.initials: N
authors.lastname: Kluger
authors.forename: R
authors.initials: R
authors.lastname: Navarro
authors.forename: V
authors.initials: V
authors.lastname: Pallure
authors.forename: B
authors.initials: B
authors.lastname: Guillot
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D001323:Autoantibodies / Q000096:biosynthesis / Q000276:immunology*; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology; D002990:Clobetasol / Q000627:therapeutic use; D005169:Factor VIII / Q000276:immunology*; D015942:Factor VIIa / Q000627:therapeutic use; D006467:Hemophilia A / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D010391:Pemphigoid, Bullous / Q000150:complications* / Q000188:drug therapy; D011994:Recombinant Proteins / Q000627:therapeutic use; D000069283:Rituximab; D016312:Treatment Refusal
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D001323:Autoantibodies; D007166:Immunosuppressive Agents; D011994:Recombinant Proteins; D000069283:Rituximab; D005169:Factor VIII; C103587:recombinant FVIIa; D002990:Clobetasol; D015942:Factor VIIa; D008727:Methotrexate